DRDaria V. Ryzhkova

Daria V. Ryzhkova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daria V. Ryzhkova has a total of 433 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dose-dependent alterations in the metabolome during radiation nephropathy: current insights and biomarker discovery prospects

    by Yu. V. Shiryaeva, N. V. Mikhailova, D. V. Ryzhkova, Ю. В. Ширяева, Н. В. Михайлова, Д. В. Рыжкова

    Ionizing radiation has a pronounced nephrotoxic effect, initiating a cascade of pathophysiological processes leading to the development of radiation nephropathy (RN) and renal failure. This review is devoted to an analysis of the current state of research in the field of identifying metabolomic biomarkers that allow for early diagnosis and prediction of radiationinduced kidney damage under external irradiation. The paper systematizes literature data obtained using mass spectrometry (MS) and nuclear magnetic resonance (NMR) regarding changes in the profiles of lowmolecularweight metabolites in urine. The main focus is on profound disturbances in purine metabolism (primarily due to the accumulation of xanthine and hypoxanthine), critical shifts in the tricarboxylic acid cycle (TCA), reflecting mitochondrial dysfunction, as well as an imbalance in the lipid profile, including the accumulation of acylcarnitines. These metabolic alterations are key indicators of oxidative stress and proximal tubule dysfunction, and the degree of their severity directly correlates with clinical and dosimetric parameters. The review provides a detailed examination of critical dose thresholds: moderate functional changes manifest when the absorbed dose to the kidneys exceeds 4 Gy, while irreversible structural degradation and manifest RN develop when the threshold of 10 Gy is exceeded. The authors emphasize that the introduction of metabolomic profiling into clinical practice can radically improve the effectiveness of monitoring the condition of patients who have undergone radiation exposure. Unlike classical protein damage markers (NGAL, KIM1), which are sensitive only at late stages, dynamic patterns of acylcarnitines, TCA cycle intermediates, and purine metabolites make it possible to carry out early biodosimetry. This makes it possible not only to detect the fact of radiation damage but also to assess the received radiation dose in the very first hours after exposure, enabling timely nephroprotective therapy.

  • Open Access

    Positron-emission tomography with 18F-fluorodeoxyglucose in a patient with acromegaly

    by A. I. Tsiberkin, D. V. Ryzhkova, U. A. Tsoy, A. A. Paltsev, E. N. Grineva, А. И. Циберкин, Д. В. Рыжкова, У. А. Цой, А. А. Пальцев, Е. Н. Гринева

    Acromegaly is a rare neuroendocrine disorder caused by autonomous hyperproduction of growth hormone, most commonly due to a pituitary adenoma, which accounts for more than 95% of cases. Magnetic resonance imaging (MRI) is the standard imaging modality for this condition; however, it cannot be performed in some patients, for example due to the presence of MRIincompatible metallic implants, which creates diagnostic challenges in determining indications for surgical treatment. We report the case of a 59-year-old patient with biochemically confirmed acromegaly in whom MRI was contraindicated because of an iron-containing metallic fixation device in the clavicular region placed after a fracture. Contrast-enhanced computed tomography (CT) revealed pituitary enlargement but did not provide sufficient diagnostic accuracy. For lesion localization, positron emission tomography combined with computed tomography (PET/CT) using 18 F-fluorodeoxyglucose (18F-FDG) was performed and demonstrated a focus of increased radiotracer uptake in the sellar region. Based on these findings, the patient underwent transsphenoidal adenomectomy. The diagnosis of somatotropinoma was confirmed by immunohistochemistry, with growth hormone expression detected in 100% of tumor cells. Following surgery, the patient achieved remission of acromegaly. This case suggests that 18 F-FDG PET/CT may serve as an alternative modality for lesion localization in acromegaly when MRI is not feasible or is contraindicated. The diagnostic performance and clinical role of this method require further investigation.

  • Open Access

    A comparative analysis of clinical, laboratory, imaging, and pathological characteristics of various variants of amyloid cardiomyopathy based on local registry data

    by P. M. Murtazalieva, D. D. Vakunenkova, D. V. Ryzhkova, E. G. Malev, L. B. Mitrofanova, T. V. Krasnikova, O. M. Moiseeva

    Aim . To characterize the phenotypic characteristics and diagnostic principles of va­rious variants of amyloid cardiomyopathy based on local registry data. Material and methods . From 2017 to 2025, 195 patients with suspected cardiac amyloidosis were examined. The diagnosis was verified in 103 patients. Transthyretin (ATTR) amyloidosis was diagnosed in 63 patients (61,2%), and light-chain (AL) amyloidosis — in 40 patients (38,8%). Most patients with ATTR amyloidosis (79%) were diagnosed using a noninvasive algorithm, including bone scintigraphy with radiopharmaceutical and hematological tests to rule out AL amyloidosis. Results . Patients with wild-type ATTR (ATTRwt) were older and had a higher prevalence of hypertension, while patients with AL amyloidosis were younger. Class III-IV heart failure was more common in the ATTRwt and AL groups compared to ATTRv amyloidosis (41%, 53%, and 21%, respectively, pConclusion . Despite the high prevalence of AL amyloidosis, transthyretin amylo­idosis appears to be the predominant cause of cardiology consultations. The high mortality rate associated with AL amyloidosis cannot be ruled out as an influence on registry studies of various types of amyloidosis. A noninvasive algorithm, inclu­ding bone scan and hematological tests, has proven high diagnostic value in verifying the diagnosis of ATTR amyloidosis. However, if laboratory testing reveals abnormalities, morphological verification of the diagnosis is indicated. Given the restrictive physiology, standard therapy for heart failure in amyloid cardiomyopathy requires significant modification.

  • Open Access

    PET/CT in topical diagnostics of recurrent medullary thyroid cancer: which radiopharmaceutical is preferred?

    by N. V. Tsentr, D. V. Ryzhkova

    Introduction. Medullary thyroid cancer (MTC) is characterized by a high risk of recurrence in the postoperative period, for the topographic localization of which, standard imaging methods are not sufficiently effective. Determination of the level of calcitonin and CEA is key test for monitoring the appearance of recurrent tumor foci, but does not indicate their localization. Based on the accumulated global experience, it has been established that the most promising methods for determining local recurrence and localization of metastases of MTC are PET/CT with [18F]-DOPA and [68Ga]-DOTA-peptides, however, data on their comparative effectiveness remain controversial. The objective was to perform an analytical comparison of the diagnostic capabilities of PET/CT with [18F]-DOPA and [68Ga]-DOTA-peptides for the topographic diagnosis of recurrent foci and assessment of the tumor burden in biochemical recurrence of MTC. Methods and materials. A retrospective analysis of studies of 100 patients with biochemical recurrence of MTC (calcitonin level> 10 pg/ml) who underwent PET/CT with [68Ga]-DOTA-peptides and/or with [18F]-DOPA, including the study of 31 patients with both radiopharmaceuticals. The analysis included an assessment of the number, localization and intensity of the accumulation foci of radiopharmaceuticals, an assessment of the correlation of the basal serum calcitonin level and the results of PET/CT. Results . In 67 out of 100 patients (67%), recurrent foci were detected using PET/CT. Direct comparison of PET/CT scans with [68Ga]-DOTA-peptides and [18F]-DOPA in 31 patients did not show any statistically significant differences in the number of lesions detected between the two radiopharmaceuticals (Wilcoxon – 1.667, p=0.096). However, in some cases, discordant results were observed: in 2 patients, [18F]-DOPA revealed more foci (in the lymph nodes, liver, and bones), and in 1 patient, [68Ga]-DOTA-peptides showed significantly higher contrast of the foci. With serum basal calcitonin values below 150 pg/ml, tumor foci were detected in almost half of PET/CT patients with both [18F]-DOPA (45 %) and [68Ga]-DOT peptides (42 %). There was only a moderate positive correlation between the level of the cancer marker and the number of detected foci (Spearman 0.47 and 0.35, for [18F]-DOPA and [68Ga]-DOT peptides, respectively, pConclusion. PET/CT with [18F]-DOPA and with [68Ga]-DOTA-peptides are highly informative for the topographic diagnosis of recurrent tumor foci in MTC with comparable diagnostic efficiency. In cases of common forms of MTC, it is preferable to perform a comprehensive PET/CT scan using both radiopharmaceuticals, which will ensure maximum diagnostic accuracy and determine the future strategy of personalized treatment.

  • Open Access

    Potential of Dual-Phase 68Ga-FAPI PET/CT in the Differential Diagnosis of Focal Liver Lesions

    by A. A. Ivanova, D. V. Ryzhkova, K. E. Sanarova, I. O. Rutkin, A. A. Stanzhevskii, A. A. Maystrenko, D. N. Maystrenko

    Introduction. Recent studies have confirmed the effectiveness of positron emission tomography combined with computed tomography (PET/CT) using radiolabeled ligands of fibroblast activation protein inhibitors (FAPI) for the visualization of malignant lesions (ML) and benign lesions (BL). The objective was to evaluate the diagnostic utility of dual-phase PET/CT with 68 Ga-FAPI-04 in patients with focal liver lesions of varying etiology. Methods and materials. The study enrolled 62 patients with focal liver lesions of diverse etiologies for the purpose of differential diagnosis (20/62 patients) and pretreatment staging (42/62 patients). 68 Ga-FAPI-04 PET/CT imaging was performed in two phases: Phase I (PET/CT 20 ) – imaging began 20 minutes after administration of 68 Ga-FAPI-04 (limited to the abdominal region); Phase II (PET/CT 60 ) – 60 minutes after injection, performed as a «Whole-body» scan. Image analysis included visual assessment and calculation of the maximum standardized uptake value (SUVmax) over the lesion areas. Results. Comprehensive clinical and imaging evaluation identified a total of 128 focal liver lesions. At the early-phase PET/CT scan (PET/CT 20 ), increased 68 Ga-FAPI-04 uptake was observed in 109 of 128 lesions (85.2 %): 18 of 25 BL and 91 of 103 ML. A comparable uptake pattern was seen on the delayed-phase scan (PET/CT 60 ): 18 of 25 BL and 93 of 103 ML. Visual and quantitative analyses of dual-phase 68 Ga-FAPI-04 PET/CT demonstrated no significant differences in sensitivity, specificity, and diagnostic accuracy between phase I and phase II for the differential diagnosis of focal liver lesions. Visual assessment yielded values of 88.3 %, 28 %, 76.6 % for phase I versus 90.3 %, 28 %, 78.1 % for phase II. Quantitative analysis of 68 Ga-FAPI-04 uptake intensity in hepatic lesions showed corresponding values of 73.8 %, 64 %, 74.2 % for phase I and 68 %, 72 %, 71.6 % for phase II. Conclusion: Elevated 68 Ga-FAPI-04 uptake was observed in the majority of hepatic lesions during both early and delayed imaging phases, irrespective of lesion etiology. Given the absence of significant diagnostic gain between time points, dual-phase PET/CT acquisition appears unnecessary for differentiating the etiology of liver lesions. Quantitative assessment using SUVmax values contributes to improved specificity of 68 Ga-FAPI-04 PET/CT in identifying malignant hepatic involvement.

  • Open Access

    DIAGNOSTIC CAPABILITIES OF [18F]FDG PET/CT IN CASES OF ENDOMETRIAL CANCER: COMPARISON WITH THE RESULTS OF MORPHOLOGICAL EXAMINATION

    by E. E. Komlichenko, E. V. Lanskaya, E. L. Dikareva, E. V. Komlichenko, E. G. Koshevaya, L. B. Mitrofanova, G. A. Raskin, E. A. Ulrikh, D. V. Ryzhkova

    Background: endometrial cancer is a common oncological disease of the female reproductive system. Treatment is based on a comprehensive analysis of FIGO staging, degree of differentiation, invasion, and molecular genetic profile of the tumor. Objective: comparative analysis of the metabolic characteristics of the primary tumor based on PET/CT results with [18F]FDG and key prognostic factors of endometrial cancer according to morphological and immunohistochemical studies. Design and methods: A retrospective analysis of 34 patients with morphologically verified endometrial cancer who underwent PET/CT prior to surgical treatment with [18F]FDG. The relationship between the quantitative metabolic characteristics of the primary tumor: the standardized accumulation level (SUVmax), the metabolic volume of the tumor (MTV) and the total glycolytic index (TLG) of the primary tumor with the histological type, degree of differentiation (Grade), the depth of invasion into the myometrium, the presence of lymphovascular invasion and damage to the lymph nodes was investigated. Results: A statistically significant strong positive correlation was found between SUVmax and the degree of neoplasm anaplasia (p=0.68, p0.001). The SUVmax values significantly differed between the Grade groups: Grade 1 – 7.25, Grade 2 – 7.22, and Grade 3 – 12.80 (p0.001). Non-endometrioid histological types and the presence of LVI were also associated with higher values of SUVmax, MTV, and TLG. A moderate positive correlation of SUVmax with the depth of tumor invasion into the myometrium was found (p=0.58, p=0.001). Conclusion: quantitative metabolic characteristics of the primary tumor obtained by PET/CT scans with [18F]FDG can be used for predictive risk stratification as part of a personalized approach to endometrial cancer treatment, as they are closely related to the main histopathological prognostic factors of biological tumor aggressiveness.

  • Imaging of active bioprosthetic valve degeneration using 68GA-FAPI-04 PET/CT: a pilot study of pathophysiological mechanisms and diagnostic value

    by A. D. Majstrenko, A. A. Ivanova, A. A. Stanzhevskij, V. E. Uspenskij, D. V. Ryzhkova, A. A. Popova, E. B. Ioffe, V. V. Zjuleva, A. Ju. Kneev, M. Gordeev

    Structural valve deterioration (SVD) remains the major limitation of bioprosthetic heart valves (BHV). Current imaging modalities (Echocardiography, CT) detect SVD at late stages of irreversible damage. This study aimed to evaluate the potential of 68Ga-FAPI-04 PET/CT, a marker of fibroblast activation, for the early visualization of active BHV remodeling and to assess its correlation with hemodynamic dysfunction. We performed a cross-sectional analysis of 30 patients with implanted aortic BHVs. All patients underwent transthoracic echocardiography and 68Ga-FAPI-04 PET/CT. Tracer uptake was quantified using the Differential Uptake Ratio (DUR). Statistical analysis included Spearman’s rank correlation, partial correlation to adjust for confounders, bootstrap analysis (5,000 resamples) for verification, and ROC analysis to determine diagnostic accuracy. DUR demonstrated a statistically significant positive correlation with peak transprosthetic pressure gradient (rs = 0.404, p = 0.027). Notably, an inverse correlation was observed between DUR and Left Ventricular Ejection Fraction (rs =–0.411, p = 0.024). Partial correlation analysis confirmed that the association between DUR and prosthetic gradients remained significant (rpartial = 0.385, p = 0.036) even after adjusting for LVEF, indicating that tracer uptake reflects intrinsic valve pathology rather than systemic heart failure. The intensity of FAP-targeted signal did not correlate with patient age or time since implantation (p >0.05). Specificity analysis showed no association between DUR and comorbidities (diabetes, renal failure) or gender. ROC analysis yielded an AUC of 0.682 (95 % CI: 0.478–0.887) for detecting severe dysfunction, with an optimal cut-off value of DUR > 2.35. The method visualizes active fibroblast-mediated remodeling in bioprosthetic valves, which correlates with hemodynamic deterioration but occurs independently of chronologic valve age and provides a specific molecular signal of SVD that is distinct from systemic factors or cardiac performance artifacts.

  • The impact of SSTR2 expression on the aggressive and recurrent course of WHO Grade I–II meningiomas

    by N. K. Samochernykh, D. A. Gulyaev, N/ V. Osipova, D. S. Romashkina, L. B. Mitrofanova, D. V. Ryzhkova, K. A. Samochernykh

    INTRODUCTION . Somatostatin receptor type 2 (SSTR2) is an important biomarker for meningiomas and is widely used in diagnosis and therapy due to its high expression frequency in tumor tissue. Despite extensive study of SSTR2, its association with the aggressive and recurrent course of WHO Grade I–II meningiomas remains poorly defined. Understanding the role of receptor expression may have implications for disease prognosis and the selection of targeted therapy.AIM. To evaluate the effect of SSTR2 expression on the aggressive and recurrent course of Grade I–II meningiomas. MATERIALS AND METHODS . The study included 20 histological specimens of Grade I–II meningiomas, divided into a study group (n=11) with an aggressive or recurrent course and a control group (n=9) without these features. SSTR2 expression was assessed by immunohistochemistry with quantitative determination of the proportion of positively stained cells in five fields of view. Statistical analysis included the Shapiro – Wilk test, Levene’s test, Mann – Whitney U-test, Spearman correlation analysis and linear regression. Significance was set at pRESULTS . The average SSTR2 expression was 31.3 % in the study group and 40.7 % in the control group. Normal distribution was confirmed only in the study group. No significant differences were found when comparing the groups (Mann – Whitney U = 46.0; p=0.820). Correlations between individual visual fields and the final expression value were high (r=0.87–0.94; pCONCLUSION . In the studied sample, SSTR2 expression levels did not demonstrate a statistically significant association with aggressive or recurrent Grade I–II meningiomas. However, the observed visual trends and heterogeneity in expression levels suggest the possibility of biological differences that require verification in larger samples. SSTR2 remains a valuable diagnostic and potential prognostic marker, and further study will allow for the optimization of targeted therapy approaches for meningiomas.

  • Clinical significance of assessing right ventricular metabolism and perfusion using positron emission tomography combined with computed tomography in patients with pulmonary arterial hypertension: a literature review

    by A. S. Malanova, N. S. Goncharova, D. V. Ryzhkova

    Pulmonary arterial hypertension (PAH) is a hemodynamic and pathophysiological condition associated with high mortality due to right ventricular (RV) heart failure. Modern diagnostic methods confirm the already existing RV remodeling and dysfunction. The search for non-invasive diagnostic methods that can detect early signs of RV myocardial dysadaptation is critical for adequate mortality risk stratification and assessing the effect of therapy to select the optimal management stra­tegy and improve prognosis in patients with PAH. This review focuses on positron emission tomography combined with computed tomography (PET/CT) in patients with PAH. PET/CT makes it possible to analyze disease mechanisms at the level of tissue metabolism and perfusion, which is not possible with traditional diagnostic methods. PET/CT may eventually become an important tool in search for new therapeutic targets and a personalized approach to treating patients with PAH.

  • Open Access

    Comparative Performance of 68Ga-FAPI-04 and ¹8F-FDG PET/CT for Detection of Malignant Tumors and Metastases

    by Анна Александровна Иванова, Дарья Викторовна Рыжкова, Андрей Алексеевич Станжевский, Ксения Евгеньевна Санарова, Дарья Андреевна Важенина, Алексей Дмитриевич Майстренко, Максим Владимирович Артемов, Дмитрий Николаевич Майстренко

    Введение. Данные о диагностическом преимуществе радиофармацевтического лекарственного препарата (РФЛП) на основе ингибитора белка активации фибробластов (68Ga-ФАПИ-04) над хорошо себя зарекомендовавшим в онкологии туморотропным РФЛП 18F-ФДГ (18F-фтордезоксиглюкозой) изучены недостаточно на небольших когортах пациентов, а доступные литературные сведения противоречивы. Цель. — Выполнить сравнительный анализ информативности позитронно-эмиссионной томографии, совмещенной с рентгеновской компьютерной томографией (ПЭТ/КТ), с 68Ga-ФАПИ-04 и 18F-ФДГ в идентификации злокачественных опухолей и их метастазов. Материалы и методы. В исследование включено 66 пациентов: 30 мужчин и 36 женщин, медиана возраста — 54 года (22-83 года), с гистологически верифицированными злокачественными новообразованиями (ЗНО) различных локализаций. ПЭТ/КТ с двумя РФЛП — 68Ga-ФАПИ-04 и 18F-ФДГ, выполнена до начала противоопухолевого лечения 34 (52 %) из 66 пациентов с целью стадирования опухолевого процесса, 32 (48 %) пациентам ПЭТ/КТ проводили с целью диагностики местного рецидива опухоли и метастазов. Интервал между исследованиями не превышал семь дней. Результаты. Чувствительность 68Ga-ФАПИ-04 в выявлении как первичной опухоли, так и оценки распространенности заболевания была достоверно выше чувствительности 18F-ФДГ и составила 93,9 против 77,3 %, p = 0,006. У 33 (97,1 %) из 34 пациентов с первичными новообразованиями была выявлена патологическая гиперфиксация 68Ga-ФАПИ-04 в опухоли, при ПЭТ/КТ с 18F-ФДГ факт наличия первичной опухоли был установлен только в 24 случаях (70,6 %). Общий объем гиперэкспрессии белка активации фибробластов (fibroblast activation protein, FAP) был достоверно выше при исследовании с 68Ga-ФАПИ-04, чем общий метаболический объем опухоли (total metabolic tumor volume, TMTV) при ПЭТ/КТ с 18F-ФДГ: 34,7 (11;75,66) против 11,07 (0; 49,5) (p = 0,021). Чувствительность в выявлении костных метастазов и метастазов в печень была выше при исследовании с 68Ga-ФАПИ-04 по сравнению c 18F-ФДГ (92,6 против 85,2 %, p = 0,046; и 90,2 против 68,3 % соответственно, p = 0,014). Чувствительность ПЭТ/КТ в выявлении метастазов в лимфатические узлы была выше для 68Ga-ФАПИ-04 (81,1 против 73 % соответственно, p = 0,044), но зависела от размеров лимфатических узлов. Выводы. ПЭТ/КТ с 68Ga-ФАПИ-04 превосходит по чувствительности ПЭТ/КТ 18F-ФДГ в идентификации первичной и рецидивной опухоли, а также метастатической диссеминации и опухолевой нагрузки.